
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of January, 2020

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd.

(Translation of registrant's name into English)

**5 Badner St.
Ramat Gan,
4365603, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

RAMAT GAN, ISRAEL — (January 29, 2020) XTL Biopharmaceuticals Ltd. (the “Company”) announces today the results of the Annual General Meeting of shareholders of the Company, held today, Wednesday, January 29, 2020, in Bnei Brak, Israel (the “Meeting”). At the Meeting, all the proposals set forth in Company’s announcement dated December 18, 2019 and an amendment thereof dated January 13, 2020 sent in connection with the Meeting were approved by the required majority of shareholders. The resolutions were as follows:

1. To approve the re-appointment of Kesselman& Kesselman, Israel CPAs, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the year ending December 31, 2019 and until our next annual general meeting of shareholders, and to authorize the Company’s Board of Directors to fix such accounting firm’s annual compensation.
2. To re-elect Messrs. Alexander Rabinovitch, Dr. Jonathan Schapiro, Shlomo Shalev, Doron Turgeman and Dr. Dobroslav Melamed to hold office as directors in the Company, commencing on the date of the Meeting and until the next Annual General Meeting of Shareholders.
3. To elect Mrs. Iris Shapira Yalon to hold office as external director of the Company Board of Directors, commencing as of the Meeting date and for a period of Three (3) years thereon.
4. To approve the appointment of Doron Turgeman as Chief Executive Officer of the Company, including his terms of employment in such capacity.

About XTL Biopharmaceuticals Ltd. (XTL)

XTL Biopharmaceuticals Ltd., is a clinical-stage biotech company. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SS). The few treatments currently on the market for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

For further information, please contact:

Investor Relations, XTL Biopharmaceuticals Ltd.

Tel: +972 3 611 6666
Email: ir@xtlbio.com
www.xtlbio.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

XTL BIOPHARMACEUTICALS LTD.

Date: January 29, 2020

By: /s/ Doron Turgeman
Doron Turgeman
Chief Executive Officer